Brokerages Set Adaptimmune Therapeutics PLC (ADAP) Target Price at $12.38

Shares of Adaptimmune Therapeutics PLC (NASDAQ:ADAP) have been assigned an average recommendation of “Hold” from the eight ratings firms that are currently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and four have given a buy recommendation to the company. The average 1 year price target among brokers that have covered the stock in the last year is $11.58.

A number of research analysts have weighed in on ADAP shares. SunTrust Banks, Inc. restated a “buy” rating and issued a $10.00 price target on shares of Adaptimmune Therapeutics PLC in a research note on Thursday. Zacks Investment Research upgraded Adaptimmune Therapeutics PLC from a “hold” rating to a “buy” rating and set a $9.75 target price for the company in a research note on Wednesday, October 4th. BidaskClub upgraded Adaptimmune Therapeutics PLC from a “sell” rating to a “hold” rating in a research note on Sunday, July 16th. Leerink Swann reiterated an “outperform” rating and set a $15.00 target price on shares of Adaptimmune Therapeutics PLC in a research note on Friday, September 8th. Finally, ValuEngine upgraded Adaptimmune Therapeutics PLC from a “strong sell” rating to a “sell” rating in a research note on Thursday, July 20th.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Alps Advisors Inc. boosted its stake in shares of Adaptimmune Therapeutics PLC by 4.9% during the 2nd quarter. Alps Advisors Inc. now owns 63,892 shares of the biotechnology company’s stock worth $287,000 after acquiring an additional 2,996 shares during the period. Raymond James Financial Services Advisors Inc. bought a new position in shares of Adaptimmune Therapeutics PLC during the 1st quarter worth approximately $120,000. KCG Holdings Inc. bought a new position in shares of Adaptimmune Therapeutics PLC during the 1st quarter worth approximately $133,000. Virtu KCG Holdings LLC boosted its stake in shares of Adaptimmune Therapeutics PLC by 108.0% during the 2nd quarter. Virtu KCG Holdings LLC now owns 50,279 shares of the biotechnology company’s stock worth $226,000 after acquiring an additional 26,105 shares during the period. Finally, Paloma Partners Management Co bought a new position in shares of Adaptimmune Therapeutics PLC during the 1st quarter worth approximately $165,000. Institutional investors own 68.01% of the company’s stock.

Shares of Adaptimmune Therapeutics PLC (ADAP) traded down 1.02% during midday trading on Friday, reaching $7.76. The company’s stock had a trading volume of 256,152 shares. The company has a 50-day moving average price of $8.39 and a 200-day moving average price of $8.39. Adaptimmune Therapeutics PLC has a 12 month low of $3.76 and a 12 month high of $9.29. The firm’s market cap is $725.71 million.

Adaptimmune Therapeutics PLC (NASDAQ:ADAP) last posted its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.24) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.24). The firm had revenue of $3.52 million during the quarter, compared to the consensus estimate of $5.43 million. Adaptimmune Therapeutics PLC had a negative return on equity of 38.73% and a negative net margin of 438.00%. Equities analysts expect that Adaptimmune Therapeutics PLC will post ($0.99) earnings per share for the current year.

WARNING: “Brokerages Set Adaptimmune Therapeutics PLC (ADAP) Target Price at $12.38” was originally reported by Markets Daily and is the sole property of of Markets Daily. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://www.themarketsdaily.com/2017/10/13/brokerages-set-adaptimmune-therapeutics-plc-adap-target-price-at-12-38.html.

About Adaptimmune Therapeutics PLC

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.

Analyst Recommendations for Adaptimmune Therapeutics PLC (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply